YS vs. RLYB, LABP, MNOV, SCYX, VHAQ, CARM, VTVT, DERM, MURA, and ASMB
Should you be buying YS Biopharma stock or one of its competitors? The main competitors of YS Biopharma include Rallybio (RLYB), Landos Biopharma (LABP), MediciNova (MNOV), SCYNEXIS (SCYX), Viveon Health Acquisition (VHAQ), Carisma Therapeutics (CARM), vTv Therapeutics (VTVT), Journey Medical (DERM), Mural Oncology (MURA), and Assembly Biosciences (ASMB). These companies are all part of the "pharmaceutical preparations" industry.
YS Biopharma (NASDAQ:YS) and Rallybio (NASDAQ:RLYB) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, community ranking, valuation, profitability, risk, dividends, earnings and analyst recommendations.
YS Biopharma presently has a consensus price target of $5.25, suggesting a potential upside of 573.08%. Rallybio has a consensus price target of $12.20, suggesting a potential upside of 535.42%. Given YS Biopharma's stronger consensus rating and higher possible upside, equities analysts plainly believe YS Biopharma is more favorable than Rallybio.
Rallybio received 31 more outperform votes than YS Biopharma when rated by MarketBeat users. However, 100.00% of users gave YS Biopharma an outperform vote while only 74.42% of users gave Rallybio an outperform vote.
52.6% of YS Biopharma shares are owned by institutional investors. Comparatively, 90.3% of Rallybio shares are owned by institutional investors. 7.4% of Rallybio shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
YS Biopharma has a beta of 0.51, meaning that its stock price is 49% less volatile than the S&P 500. Comparatively, Rallybio has a beta of -1.63, meaning that its stock price is 263% less volatile than the S&P 500.
In the previous week, YS Biopharma had 1 more articles in the media than Rallybio. MarketBeat recorded 2 mentions for YS Biopharma and 1 mentions for Rallybio. YS Biopharma's average media sentiment score of 0.73 beat Rallybio's score of 0.00 indicating that YS Biopharma is being referred to more favorably in the media.
YS Biopharma's return on equity of 0.00% beat Rallybio's return on equity.
YS Biopharma has higher revenue and earnings than Rallybio.
Summary
YS Biopharma beats Rallybio on 10 of the 14 factors compared between the two stocks.
Get YS Biopharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for YS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding YS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
YS Biopharma Competitors List
Related Companies and Tools
